Home / Recalls / Drug Depot, Inc., dba APS Pharmacy / D-0731-2022

D-0731-2022 Class II Terminated

Recalled by Drug Depot, Inc., dba APS Pharmacy — Palm Harbor, FL

FDA drug recall D-0731-2022 was initiated by Drug Depot, Inc., dba APS Pharmacy on March 23, 2022 and is designated Class II. Reason for recall: Lack of sterility assurance. The recall status is terminated (terminated October 5, 2023). Affected quantity: 73 vials.

Recall Details

Product Type: Drugs
Report Date: April 6, 2022
Initiation Date: March 23, 2022
Termination Date: October 5, 2023
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 73 vials

Product Description

TESTOSTERONE CYPIONATE/ ANASTROZOLE *GS* OIL (10ML) 200MG/0.5MG/ML; Packaged in a multi dose 10ML vial, as a) (CA) 4 ML Formula ID 136164; b) (RM) 10 ML Formula ID 115962; APS Phar

Reason for Recall

Lack of sterility assurance.

Distribution Pattern

Nationwide in the USA including Puerto Rico.

Code Information

Lots: a)750851 BUD: 7/18/2022; b) 754549 BUD: 8/2/2022

Other recalls by Drug Depot, Inc., dba APS Pharmacy

D-0734-2022 Class II — TESTOSTERONE CYPIONATE *GS* Oil 200 MG/ML Injectable, Packaged in a multi dose 1 (March 23, 2022)
D-0733-2022 Class II — TESTOSTERONE CYPIONATE/PROPIONATE *SES* Oil (10 ML) 160MG/20MG/ML Injectable, Pa (March 23, 2022)
D-0730-2022 Class II — TESTOSTERONE CYPIONATE/ANASTROZOLE *GS* OIL 200MG/1MG/ML Injectable, Packaged i (March 23, 2022)
D-0735-2022 Class II — TESTOSTERONE CYPIONATE *GS* (2 mL) 80 MG/ML Injectable, Packaged in a multi dos (March 23, 2022)
D-0728-2022 Class II — GONADORELIN (5ML) 0.2 MG/ML INJECTABLE, Packaged in a multi dose 10ML vial, Form (March 23, 2022)
D-0732-2022 Class II — TESTOSTERONE CYPIONATE/ DHEA *GS* 200/10MG/ML Injectable, Packaged in a multi do (March 23, 2022)
D-0729-2022 Class II — (CA) GONADORELIN (4ML) 0.2 MG/ML INJECTABLE, Packaged in a multi dose 10ML vial, (March 23, 2022)